Skip to main content

Advertisement

SpringerLink
Log in

The European Medicines Agency's strategies to meet the challenges of Alzheimer disease

  • Comment
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Abstract

Regulatory agencies have a key role in facilitating the development of new drugs for Alzheimer disease, particularly given the challenges associated with early intervention. Here, we highlight the strategies of the European Medicines Agency to help address such challenges.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Author notes

  1. Manuel Haas, Valentina Mantua and Marion Haberkamp: These authors contributed equally to this work.

Authors and Affiliations

  1. European Medicines Agency, 30 Churchill Place, Canary Wharf, London, E14 5EU, United Kingdom

    Manuel Haas, Maria Isaac, Florence Butlen-Ducuing & Spiros Vamvakas

  2. Agenzia Italiana del Farmaco, Via del Tritone 181, Rome, 00187, Italy

    Valentina Mantua & Luca Pani

  3. Bundesinstitut für Arzneimittel und Medizinprodukte, Kurt-Georg-Kiesinger-Allee 3, Bonn, 53175, Germany

    Marion Haberkamp & Karl Broich

Authors
  1. Manuel Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valentina Mantua
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marion Haberkamp
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luca Pani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria Isaac
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Florence Butlen-Ducuing
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Spiros Vamvakas
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Karl Broich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manuel Haas.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

Related links

FURTHER INFORMATION

Qualification opinion of Alzheimer's disease novel methodologies/biomarkers

Qualification opinion of novel methodologies in the pre-dementia stage of Alzheimer's disease: cerebrospinal fluid related biomarkers for drugs affecting amyloid burden

Qualification opinion of low hippocampal volume (atrophy) by MRI for use in clinical trials for regulatory purpose - in pre-dementia stage of Alzheimer's disease

Qualification opinion of Alzheimer's disease novel methodologies/biomarkers for the use of CSF AB 1-42 and t-tau and/or PET-amyloid imaging (positive/ negative) as biomarkers for enrichment

Qualification opinion of a novel data driven model of disease progression and trial evaluation in mild and moderate Alzheimer's disease

EMA Discussion Paper

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Haas, M., Mantua, V., Haberkamp, M. et al. The European Medicines Agency's strategies to meet the challenges of Alzheimer disease. Nat Rev Drug Discov 14, 221–222 (2015). https://doi.org/10.1038/nrd4585

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4585

  • Springer Nature Limited

This article is cited by

Search

Navigation